Limits...
Mangrove rare actinobacteria: taxonomy, natural compound, and discovery of bioactivity.

Azman AS, Othman I, Velu SS, Chan KG, Lee LH - Front Microbiol (2015)

Bottom Line: As a result, there is a dramatic increase in demand to look for new compounds which have pharmacological properties from another group of Actinobacteria, known as rare actinobacteria; which is isolated from special environments such as mangrove.Many novel compounds discovered from the novel rare actinobacteria have been proven as potential new drugs in medical and pharmaceutical industries such as antibiotics, antimicrobials, antibacterials, anticancer, and antifungals.This review article highlights the latest studies on the discovery of natural compounds from the novel mangrove rare actinobacteria and provides insight on the impact of these findings.

View Article: PubMed Central - PubMed

Affiliation: Jeffrey Cheah School of Medicine and Health Sciences, Monash University Sunway Campus Selangor, Malaysia.

ABSTRACT
Actinobacteria are one of the most important and efficient groups of natural metabolite producers. The genus Streptomyces have been recognized as prolific producers of useful natural compounds as they produced more than half of the naturally-occurring antibiotics isolated to-date and continue as the primary source of new bioactive compounds. Lately, Streptomyces groups isolated from different environments produced the same types of compound, possibly due to frequent genetic exchanges between species. As a result, there is a dramatic increase in demand to look for new compounds which have pharmacological properties from another group of Actinobacteria, known as rare actinobacteria; which is isolated from special environments such as mangrove. Recently, mangrove ecosystem is becoming a hot spot for studies of bioactivities and the discovery of natural products. Many novel compounds discovered from the novel rare actinobacteria have been proven as potential new drugs in medical and pharmaceutical industries such as antibiotics, antimicrobials, antibacterials, anticancer, and antifungals. This review article highlights the latest studies on the discovery of natural compounds from the novel mangrove rare actinobacteria and provides insight on the impact of these findings.

No MeSH data available.


Related in: MedlinePlus

The structure of rifamycin S (1) and the geometric isomer of rifamycin S (2).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4542535&req=5

Figure 1: The structure of rifamycin S (1) and the geometric isomer of rifamycin S (2).

Mentions: Currently, some Micromonospora from the mangrove environment has produced useful bioactive compounds for studies on drug discovery. Micromonospora rifamycinica AM105 was isolated from mangrove sediments from Hainan Island, South China Sea (Huang et al., 2009). The antimicrobial activity against methicillin-resistant Staphylococcus aereus (MRSA) using secondary metabolite extracts has led to the discovery of two antibiotic compounds (Figure 1), namely rifamycin S (1) and the geometric isomer of rifamycin S (2). There are different types of rifamycin, depending on its chemical structure such as rifamycin B, O, S, and SV. Rifamycin S has higher activity once it reduces to form rifamycin SV in aqueous solutions (Zhang, 2003). Also the antibacterial activity from a combination of rifamycin S and the geometric isomer of rifamycin S from Micromonospora rifamycinica AM105 was higher than rifamycin SV. This finding suggests that the antibacterial activity of the geometric isomer of rifamycin S was higher than rifamycin SV, and the antimicrobial activity of rifamycin SV was higher than rifamycin S.


Mangrove rare actinobacteria: taxonomy, natural compound, and discovery of bioactivity.

Azman AS, Othman I, Velu SS, Chan KG, Lee LH - Front Microbiol (2015)

The structure of rifamycin S (1) and the geometric isomer of rifamycin S (2).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4542535&req=5

Figure 1: The structure of rifamycin S (1) and the geometric isomer of rifamycin S (2).
Mentions: Currently, some Micromonospora from the mangrove environment has produced useful bioactive compounds for studies on drug discovery. Micromonospora rifamycinica AM105 was isolated from mangrove sediments from Hainan Island, South China Sea (Huang et al., 2009). The antimicrobial activity against methicillin-resistant Staphylococcus aereus (MRSA) using secondary metabolite extracts has led to the discovery of two antibiotic compounds (Figure 1), namely rifamycin S (1) and the geometric isomer of rifamycin S (2). There are different types of rifamycin, depending on its chemical structure such as rifamycin B, O, S, and SV. Rifamycin S has higher activity once it reduces to form rifamycin SV in aqueous solutions (Zhang, 2003). Also the antibacterial activity from a combination of rifamycin S and the geometric isomer of rifamycin S from Micromonospora rifamycinica AM105 was higher than rifamycin SV. This finding suggests that the antibacterial activity of the geometric isomer of rifamycin S was higher than rifamycin SV, and the antimicrobial activity of rifamycin SV was higher than rifamycin S.

Bottom Line: As a result, there is a dramatic increase in demand to look for new compounds which have pharmacological properties from another group of Actinobacteria, known as rare actinobacteria; which is isolated from special environments such as mangrove.Many novel compounds discovered from the novel rare actinobacteria have been proven as potential new drugs in medical and pharmaceutical industries such as antibiotics, antimicrobials, antibacterials, anticancer, and antifungals.This review article highlights the latest studies on the discovery of natural compounds from the novel mangrove rare actinobacteria and provides insight on the impact of these findings.

View Article: PubMed Central - PubMed

Affiliation: Jeffrey Cheah School of Medicine and Health Sciences, Monash University Sunway Campus Selangor, Malaysia.

ABSTRACT
Actinobacteria are one of the most important and efficient groups of natural metabolite producers. The genus Streptomyces have been recognized as prolific producers of useful natural compounds as they produced more than half of the naturally-occurring antibiotics isolated to-date and continue as the primary source of new bioactive compounds. Lately, Streptomyces groups isolated from different environments produced the same types of compound, possibly due to frequent genetic exchanges between species. As a result, there is a dramatic increase in demand to look for new compounds which have pharmacological properties from another group of Actinobacteria, known as rare actinobacteria; which is isolated from special environments such as mangrove. Recently, mangrove ecosystem is becoming a hot spot for studies of bioactivities and the discovery of natural products. Many novel compounds discovered from the novel rare actinobacteria have been proven as potential new drugs in medical and pharmaceutical industries such as antibiotics, antimicrobials, antibacterials, anticancer, and antifungals. This review article highlights the latest studies on the discovery of natural compounds from the novel mangrove rare actinobacteria and provides insight on the impact of these findings.

No MeSH data available.


Related in: MedlinePlus